CTIS2023-505509-18-00招募中1 期
B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents - B-NHL 2013
niversitaetsklinikum Muenster AöR0 个研究点目标入组 650 人开始时间: 2023年8月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •newly diagnosed, histological or cytological and immunological proven aggressive mature B-cell Non-Hodgkin lymphoma including Burkitt lymphoma (BL), Burkitt leukemia (B-AL), diffuse large B-cell lymphoma (DLBCL), or mature B-cell NHL not further classified according to current WHO classification. For rare subtypes (e.g. primary mediastinal large BNHL, PMLBL double hit lymphoma or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements), consultation of the study center is recommended, availability of slides/blocks for reference pathology and international pathology panel (except in cases with immunological and cytomorphological assurance of diagnosis), age at diagnosis < 18 years, diagnostics and treatment in one of the participating centers of the trial, no previous chemotherapy, no previous lymphoma-directed treatment. No application of steroids for more than two days during the last month, adequate hepatic, renal and cardiac function, except if alteration is due to lymphoma Infiltration. Please contact the study center in case of unclear cases, signed informed consent of patient and or parents/guardians for treatment according to the protocol, participation and transfer of data, follow-up of at least two years after initial diagnosis is expected, certificate of vaccination against hepatitis B or negative serology, defined as - evidence of immunization with HBs-antigen negative, anti-HBs positive and anti-HBc negative or - negative hepatitis B serology with HBs-antigen negative, anti- HBs and anti-HBc negative E.
排除标准
- •patients with insufficient work up not allowing a correct stratification into the risk groups, B-cell neoplasia as second malignancy, any other medical, psychiatric, or social condition prohibiting treatment according to the protocol (e.g. previous malignancy, prior organ transplant, HIV infection or AIDS or severe immunodeficiency, etc.), participation within a different trial for treatment of B-cell malignancies and/or concurrent treatment within any other clinical trial. Exceptions to this are the NHL-BFM Registry 2012 and trials with different endpoints, involving aspects of supportive treatment which can run parallel to B-NHL 2013 without influencing the outcome of this trial e.g. trials on antiemetics, antibiotics, strategies for psychosocial support etc., overt hepatitis B or history of hepatitis B, hypersensitivity to rituximab or to murine proteins, or to any of the other excipients of the Investigational Medicinal Product or to ingredients of other IMPs, lack of CD20 expression of the lymphoma cells, pregnancy and lactation
研究者
相似试验
进行中（未招募）
1 期
oEUCTR2013-003253-21-NOniversitätsklinikum Münster650
进行中（未招募）
1 期
omature aggressive B-cell lymphoma and leukemia in children and adolescentsMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-003253-21-SEniversitätsklinikum Münster650
进行中（未招募）
1 期
oEUCTR2013-003253-21-DKniversitätsklinikum Münster650
进行中（未招募）
1 期
omature aggressive B-cell lymphoma and leukemia in children and adolescentsMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-003253-21-FIniversitätsklinikum Münster650
进行中（未招募）
1 期
oEUCTR2013-003253-21-ATniversitätsklinikum Münster650